ArticleOncotarget2018

mTORC1/2 inhibition re-sensitizes platinum-resistant ovarian cancer by disrupting selective translation of DNA damage and survival mRNAs.

Gizelka David-West et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.